Trattamento dell'iperparatiroidismo secondario: calciomimetici,attivatori selettivi del recettore della vitamina D (VDRAs) o terapia combinata?

Abstract

Get full access to this article

View all access options for this article.

References

Parfitt

A.M.

The hyperparathyroidism of chronic renal failure: A disorder of growth. Kidney Int 1997; 52: 3–9.

Cozzolino

, Butti

, Chiarelli

New insights in the pathogenesis of secondary hyperparathyroidsm. G Ital Nefrol 2005; 4: 329–36.

Slatopolsky

, Finch

, Denda

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534–40.

Silver

, Bar Sela

, and Naveh-Many

Regulation of parathyroid cell proliferation. Curr Op Nephrol Hyperten 1997; 6: 321–26.

Cozzolino

, Dusso

, Slatopolsky

Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511–6.

Cozzolino

, Brancaccio

, Gallieni

, and

Slatopolsky. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429–36.

Cozzolino

, Gallieni

, Brancaccio

Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 2006; 19: 566–57.

Cozzolino

, Brancaccio

, Gallieni

Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005; 18(1): 5–8.

Brown

E.M.

, Gamba

, Riccardi

Cloning and characterization of an extracellular Ca²⁺-sensing receptor from bovine parathyroid. Nature 1993; 366: 575–80.

10.

Merke

, Hugel

, Zlotkowski

Diminished parathyroid 1,25-dihydroxyvitman D3 receptors in experimental uremia. Kidney Int 1987; 32: 350–33.

11.

Silver

, Kilav

, Naveh-Many

Mechanisms of secondary hyperparathyroidism. Am J Physiol Ren Physiol 2002; 283: F367–76.

12.

Ganesh

S.K.

, Stack

A.G.

, Levin

N.W.

Association of elevated serum PO₄, Ca x PO₄ product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–8.

13.

Marco

M.P.

, Craver

, Bertriu

Higher impact of mineral metabolism on cardiovascular mortality in an European hemodialysis population. Kidney Int 2003; 63(suppl 85): S111–4.

14.

Block

G.A.

, Klassen

P.S.

, Lazarus

J.M.

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15(8): 2208–18.

15.

Wang

A.Y.

, Wang

, Woo

Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159–68.

16.

National Kidney Foundation DOQI: Clinical Pratical Guidelines For Bone Metabolism and Disease in Chronic Kidney Diseases. Am J Kidney Dis 2003; 42(4), (Suppl 3).

17.

Mazzaferro

, Cozzolino

, Marangella

Calcimimetics, phosphate binders, vitamin D and its analouges for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. G Ital Nefrol 2007; 24(suppl 37): S107–24.

18.

Kawata

, Imanishi

, Kobayashi

Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 2005; 153(4): 587–94.

19.

Block

, Kevin

J.M.

, De Francisco

A.L.M.

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 627–35.

20.

Lindberg

J.S.

, Culleton

, Wong

Cinacalcet HCL, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A Randomized Double-Bind, Multicenter Study. J Am Soc Nephrol 2005; 16: 800–07.

21.

Moe

S.M.

, Chertow

G.M.

, Coburn

J.W.

Achieving NKF-K/DOQI TM bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 2005; 67: 760–71.

22.

Cunningham

, Danese

, Olson

, Klassen

, Chertow

G.M.

Effect of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–800.

23.

Szabo

, Merke

, Beier

1,25(OH)₂vitamin D₃ inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049–56.

24.

Bellows

C.G.

, Reimers

S.M.

, Heersche

J.N.

Expression of mRNAs for type I collagen, bone sialoprotein, osteo-calcin and osteopontin at different stages of osteoblastic differentation and their regulation by 1,25 dihydroxyvitamin D. Cell Tissue Res 1999; 297: 249–59.

25.

Sjoden

, Lindgren

J.U.

, DeLuca

H.F.

Antirachitic activity of 1 alpha-hydroxyergocholecalciferol and 1 alpha-hydroxycholecalciferol in rats. J Nutr 1984; 114: 2043–6.

26.

Brown

A.J.

, Finch

, Grieff

The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158–64.

27.

Slatopolsky

, Cozzolino

, Finch

J.L.

Differential effects of 19-nor-1,25-(OH)₂D₂ and 1alpha-hydroxyvitamin D₂ on calcium and phosphorum in normal and uremic rats. Kidney Int 2002; 62(4): 1277–84.

28.

Martin

, Gonzalez

E.A.

, Gellens

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9(8): 1427–32.

29.

Sprague

S.M.

, Llach

, Amdahl

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483–90.

30.

Teng

, Wolf

, Lowrie

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol. N Engl J Med 2003; 349: 446–56.

31.

Teng

, Wolf

, Ofsthun

M.N.

Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25.

32.

Dobrez

D.G.

, Mathes

, Amdahl

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19(5): 1174–81.